Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Core Insights - HyBryte therapy has shown positive responses in patients, with three out of four subjects achieving "Treatment Success" after at least 12 weeks of treatment [2][9] - The Phase 3 FLASH study demonstrated the efficacy and promising safety profile of HyBryte, addressing the limited treatment options for early-stage cutaneous T-cell lymphoma (CTCL) patients [4][10] - The interim update from Soligenix indicates ongoing collaboration with the FDA for further studies, including a confirmatory Phase 3 placebo-controlled study [6] Study Details - The open-label study (protocol HPN-CTCL-04) enrolled ten patients, with six patients treated for up to 44 weeks [3][13] - Initial results from the expanded use of HyBryte in a real-world setting were described as "promising," supporting previous positive Phase 2 and 3 clinical trial results [10] - Two of the three patients who achieved Treatment Success did so within the first 12 weeks, while the third achieved success at 18 weeks [9] Efficacy and Safety - The study revealed that 60% of patients treated with HyBryte achieved a 50% or better improvement in their mCAILS score, compared to 20% of patients treated with Valchlor [11] - HyBryte has been reported to have a favorable safety profile, with no treatment-related adverse events observed in all patients [14] Market Reaction - Following the positive news, Soligenix Inc (SNGX) shares surged by 221.5%, reaching $6.43, with a trading volume of 23.6 million shares [7][8]